InnoCan PharmaHAM:IP40 64 Return-on-Tangible-Asset is -36.63% as of Mar. 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 64/100 and a GF Value™ of €7.62 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,987 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 90.74% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. InnoCan Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was €-3.36 Mil. InnoCan Pharma's average total tangible assets for the quarter that ended in Mar. 2026 was €9.18 Mil. Therefore, InnoCan Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -36.63%.
The historical rank and industry rank for InnoCan Pharma's Return-on-Tangible-Asset or its related term are showing as below:
HAM:IP40'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -284.86 Med: -92.98 Max: -11.2
Current: -13.8
During the past 8 years, InnoCan Pharma's highest Return-on-Tangible-Asset was -11.20%. The lowest was -284.86%. And the median was -92.98%.
HAM:IP40's Return-on-Tangible-Asset is ranked worse than 90.74% of 1987
companies
in the Consumer Packaged Goods industry
Industry Median: 3.38
vs HAM:IP40: -13.80
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
InnoCan Pharma Return-on-Tangible-Asset Related Terms
InnoCan Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IP40 vs PG, CL, KVUE: Return-on-Tangible-Asset Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Return-on-Tangible-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -36.63% mean?
InnoCan Pharma (HAM:IP40) has a Return-on-Tangible-Asset of -36.63% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #1803 out of 1987 companies in the Consumer Packaged Goods industry, placing it in the top 90.7%.
Is InnoCan Pharma's Return-on-Tangible-Asset too high?
InnoCan Pharma's current Return-on-Tangible-Asset is -36.63%. Based on the distribution chart, InnoCan Pharma ranks #1803 out of 1987 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Return-on-Tangible-Asset compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1803 out of 1987 companies for Return-on-Tangible-Asset. This places InnoCan Pharma in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Consumer Packaged Goods company?
The median Return-on-Tangible-Asset among Consumer Packaged Goods companies is 3.38, based on 1,987 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Asset is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Return-on-Tangible-Asset is -36.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.62, compared to a current price of €1.75 — trading 77.1% below its estimated fair value. The current Return-on-Tangible-Asset is -36.63%. InnoCan Pharma's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Return-on-Tangible-Asset is -36.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.75 is trading 77.1% below its estimated GF Value™ of €7.62.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Return-on-Tangible-Asset: -36.63%
GF Value™: €7.62 vs. price of €1.75 (77.1% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
64GF Score
Get the complete analysis for HAM:IP40
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
